title: Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.
authors.affiliation: Translational Development, Celgene Corporation, Summit, NJ, USA.
authors.forename: A
authors.initials: A
authors.lastname: Thakurta
authors.affiliation: Translational Development, Celgene Corporation, Summit, NJ, USA.
authors.forename: A K
authors.initials: AK
authors.lastname: Gandhi
authors.affiliation: Translational Development, Celgene Corporation, Summit, NJ, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Waldman
authors.affiliation: Translational Development, Celgene Corporation, Summit, NJ, USA.
authors.forename: C
authors.initials: C
authors.lastname: Bjorklund
authors.affiliation: Translational Development, Celgene Corporation, Summit, NJ, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Ning
authors.affiliation: Translational Development, Celgene Corporation, Summit, NJ, USA.
authors.forename: D
authors.initials: D
authors.lastname: Mendy
authors.affiliation: Translational Development, Celgene Corporation, Summit, NJ, USA.
authors.forename: P
authors.initials: P
authors.lastname: Schafer
authors.affiliation: Translational Development, Celgene Corporation, Summit, NJ, USA.
authors.forename: A
authors.initials: A
authors.lastname: Lopez-Girona
authors.affiliation: Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
authors.forename: S
authors.initials: S
authors.lastname: Lentzsch
authors.affiliation: Department of Haemato-oncology, King's College Hospital and King's College London, London, UK.
authors.forename: S A
authors.initials: SA
authors.lastname: Schey
authors.affiliation: Department of Haemato-oncology, King's College Hospital and King's College London, London, UK.
authors.forename: Y
authors.initials: Y
authors.lastname: Calle
authors.affiliation: Department of Haemato-oncology, King's College Hospital and King's College London, London, UK.
authors.forename: R
authors.initials: R
authors.lastname: Chelliah
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: R Z
authors.initials: RZ
authors.lastname: Orlowski
authors.affiliation: Covance Genomics Laboratory, Seattle, WA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Madan
authors.affiliation: Unité de Génomique du Myélome, University Hospital, Toulouse, France.
authors.forename: H
authors.initials: H
authors.lastname: Avet-Loiseau
authors.affiliation: Translational Development, Celgene Corporation, Summit, NJ, USA.
authors.forename: R
authors.initials: R
authors.lastname: Chopra
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000235:genetics*; D006801:Humans; D000077269:Lenalidomide; D009154:Mutation; D010447:Peptide Hydrolases / Q000235:genetics*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D044767:Ubiquitin-Protein Ligases
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000276:Adjuvants, Immunologic; C502543:CRBN protein, human; C091435:DDB1 protein, human; D004268:DNA-Binding Proteins; D013792:Thalidomide; C467566:pomalidomide; D044767:Ubiquitin-Protein Ligases; D010447:Peptide Hydrolases; D000077269:Lenalidomide